Pharmacodynamic activity of MEDI9197, a TLR7/8 agonist, administered intratumorally in subjects with solid subcutaneous or cutaneous tumors

被引：0

作者：

Cooper, Zachary A. ^{[1
]}

Morehouse, Christopher A. ^{[1
]}

Wu, Yuling ^{[1
]}

Steele, Keith ^{[1
]}

Brucker, David ^{[2
]}

Tseng, Leo ^{[1
]}

Jure-Kunkel, Maria ^{[1
]}

Mueller, Nancy ^{[1
]}

Ryan, Patricia ^{[1
]}

Grilley-Olson, Juneko ^{[3
]}

Hong, David ^{[4
]}

Marabelle, Aurelien ^{[5
]}

Munster, Pamela ^{[6
]}

Aggarwal, Rahul ^{[6
]}

Aspeslagh, Sandrine ^{[5
]}

Dixon, Robert G. ^{[3
]}

Patel, Manish ^{[7
]}

Subbiah, Vivek ^{[4
]}

Brody, Joshua ^{[8
]}

Gupta, Shilpa ^{[7
]}

机构：

[1] MedImmune, Gaithersburg, MD USA

[2] Definiens, Cambridge, MA USA

[3] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Inst Gustave Roussy, F-94800 Villejuif, France

[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[7] Masonic Canc Ctr, Minneapolis, MN USA

[8] Mt Sinai Hess Ctr Sci & Med, New York, NY USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P457

引用

页数：2

共 39 条

[21] Antitumor activity of a novel dual agonist of TLR7 and TLR8 in a preclinical model of 3LL-C75 lung carcinoma in wild type, TLR7-/-, TLR9-/-, and MyD88-/- mice
Wang, Daqing
Tao, Lan
Tang, Jimmy
Kandimalla, Ekambar
Agrawal, Sudhir
CANCER RESEARCH, 2009, 69
[22] Antitumor activity of a novel dual agonist of TLR7 and TLR8 in a preclinical model of 3LL-C75 lung carcinoma in wild type, TLR7-/-, TLR94-/-, and MyD884-/- mice
Wang, Daqing
Tao, Lan
Tang, Jimmy
Kandimalla, Ekambar
Agrawal, Sudhir
CANCER RESEARCH, 2009, 69
[23] TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study
Starodub, Alexander
Kim, Sung-Bae
Davar, Diwakar
Yeku, Oladapo O.
Hill, Andrew Graham
Powderly, John D., II
Gabrail, Nashat
Krapp, Christian
Slavsky, Sibel
Castro, Davis Y. Torrejon
Singel, Stina Mui
Kwatra, Vineet
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[24] REVEAL: PHASE 1 DOSE-ESCALATION STUDY OF NKTR-262, A NOVEL TLR7/8 AGONIST, PLUS BEMPEGALDESLEUKIN: LOCAL INNATE IMMUNE ACTIVATION AND SYSTEMIC ADAPTIVE IMMUNE EXPANSION FOR TREATING SOLID TUMORS
Diab, Adi
Curti, Brendan
Bilen, Mehmet
Brohl, Andrew
Domingo-Musibay, Evidio
Borazanci, Erkut
Fanton, Christie
Haglund, Cat
Vimal, Mona
Muhsin, Mann
Marcondes, Mario
Nguyen, Anh
Tagliaferri, Mary
Lin, Wei
Zalevsky, Jonathan
D'Angelo, Sandra
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A224 - A225
[25] MEDI 573-Imidazo[4,5-c]quinoline-based TLR7 and TLR8 immune response modifiers: Structure-activity-relationships relating to potency, selectivity, and therapeutic applications
Kshirsagar, Tushar A.
Griesgraber, George W.
Stoermer, Doris
Amos, David T.
Lindstrom, Kyle J.
Rice, Michael J.
Crooks, Stephen L.
Bonk, Jason D.
Dellaria, Joseph F.
Heppner, Philip D.
Gerster, John F.
Merrill, Bryon A.
Johannessen, Sarah C.
Zimmermann, Bernhard M.
Marszalek, Gregory
Dresssel, Luke T.
Haraldson, Chad A.
Squire, David J.
Wurst, Joshua R.
Radmer, Matthew R.
Manske, Karl J.
Spessard, Sarah J.
Langer, Scott E.
Karp, Gregory P.
Gibson, Sheila J.
Wurst, Lindsay R.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
[26] Anti-CEACAM5 immune stimulant TLR7/8 agonist antibody drug conjugate is a potent myeloid cell activator for the treatment of CEACAM5-expressing tumors
Decary, Stephanie
Blot, Lydia
Lahoute, Charlotte
Benoist, Sandrine
Caron, Anne
Graziano, Francesca
Trombe, Marc
Calvet, Loreley
Ferrier, Alexandra
Frederic, Marc
Sidhu, Sukhvinder
Brun, Marie-Priscille
Chiron, Marielle
CANCER RESEARCH, 2023, 83 (07)
[27] Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Zuniga, Luis Alejandro
Lessmann, Torben
Uppal, Karan
Bisek, Nicola
Hong, Enping
Rasmussen, Caroline E.
Karlsson, Jens-Jakob
Zettler, Joachim
Holten-Andersen, Lars
Bang, Kathy
Thakar, Dhruv
Lee, Yu-Chi
Martinez, Salomon
Sabharwal, Simran Singh
Stark, Sebastian
Faltinger, Frank
Kracker, Oliver
Weisbrod, Samuel
Mueller, Robin
Voigt, Tobias
Bigott, Kornelia
Tabrizifard, Mohammad
Breinholt, Vibeke Miller
Mirza, Amer M.
Rosen, David B.
Sprogoe, Kennett
Punnonen, Juha
CANCER CELL INTERNATIONAL, 2022, 22 (01)
[28] Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Luis Alejandro Zúñiga
Torben Leßmann
Karan Uppal
Nicola Bisek
Enping Hong
Caroline E. Rasmussen
Jens-Jakob Karlsson
Joachim Zettler
Lars Holten-Andersen
Kathy Bang
Dhruv Thakar
Yu-Chi Lee
Salomon Martinez
Simran Singh Sabharwal
Sebastian Stark
Frank Faltinger
Oliver Kracker
Samuel Weisbrod
Robin Müller
Tobias Voigt
Kornelia Bigott
Mohammad Tabrizifard
Vibeke Miller Breinholt
Amer M. Mirza
David B. Rosen
Kennett Sprogøe
Juha Punnonen
Cancer Cell International, 22
[29] AGADIR: A basket multicenter open-label phase II study evaluating the first in class TLR7/8 agonist BDB001 in combination with atezolizumab and stereotactic body radiation therapy in patients with advanced solid tumors
Italiano, A.
Bergouignan, C. Coutzac
Pasquier, D.
Rochigneux, P.
Sablin, M. P.
Gomez-Roca, C. A.
Ghiringhelli, F.
Metges, J-P.
Toulmonde, M.
Cousin, S.
Pernot, S.
Auzanneau, C.
Lortal, B.
Kind, M.
Sargos, P.
Batard, S.
Petit, A.
Gillon, P.
Albert, S.
Pulido, M.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S898 - S898
[30] transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors.
Davar, Diwakar
Singel, Stina M.
Nyamuswa, Gil
Tuan-Anh Tran
Wu, Yang
Grewal, Jaspreet
Aghmesheh, Morteza
Spira, Alexander
Ganju, Vinod
Rand, Jamie
Frentzas, Sophia
Bajor, David
Gabrail, Nashat
CANCER RESEARCH, 2022, 82 (12)

← 1 2 3 4 →